Arcturus Therapeutics Highlights mRNA Innovations at Guggenheim Biotech Conference 2025

Arcturus Therapeutics Showcases mRNA Innovations at Biotech Conference

Arcturus Therapeutics Holdings Inc., a pioneering messenger RNA (mRNA) medicines company based in San Diego, announces its participation in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference scheduled for February 6, 2025. During this engagement, the company plans to highlight its innovative approaches in developing vaccines and therapies leveraging its proprietary technologies. Founded in 2013, Arcturus has established itself at the forefront of mRNA technology, particularly in addressing infectious diseases and rare conditions affecting the liver and respiratory systems.

The company’s proprietary LUNAR® lipid-mediated delivery system and STARR® mRNA Technology have positioned it as a leader in the mRNA landscape. Notably, Arcturus developed KOSTAIVE®, recognized as the world’s first self-amplifying mRNA COVID vaccine, which has garnered regulatory approval. This achievement underscores the company's commitment to advancing vaccine technology, particularly as it collaborates globally with partners such as CSL Seqirus. Through this collaboration, Arcturus aims to innovate further in the mRNA vaccine field, responding to emerging infectious disease threats with agility and precision.

In addition to its vaccine initiatives, Arcturus is actively pursuing a robust pipeline of RNA therapeutic candidates targeting critical health issues such as ornithine transcarbamylase deficiency and cystic fibrosis. The company operates ARCALIS, a joint venture in Japan dedicated to mRNA vaccine and therapeutic manufacturing, exemplifying its commitment to expanding production capabilities and global outreach. With an extensive patent portfolio exceeding 400 patents and applications worldwide, Arcturus is well-equipped to protect its innovations while advancing the field of nucleic acid medicines, including messenger RNA, small interfering RNA, and gene editing therapeutics.

Arcturus encourages stakeholders and interested parties to engage with its latest developments through its Investor Relations page and social media platforms, including Twitter and LinkedIn. The company’s participation in industry events like the Guggenheim Securities conference reflects its dedication to transparency and collaboration within the biotech community, paving the way for future advancements in mRNA technology.